Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom

Objectives: The aim of this study was to examine the availability and consistency of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer. Methods: A systematic review of UK economic evaluations of colorectal cancer interventions was undertaken. Searches were undertaken across ten electronic databases. Studies were critically appraised through reference to a conceptual model of UK colorectal cancer services. Results: Forty-seven studies met the inclusion criteria. There is a substantial economic evidence base surrounding population-level colorectal screening, surgical procedures, and cytotoxic therapies for the adjuvant and palliative treatment of colorectal cancer. There is limited evidence concerning the diagnosis of suspected colorectal cancer, curative treatments for metastatic disease and follow-up regimens for nonmetastatic disease. No studies were identified relating to the economics of radiotherapy, surveillance of increased-risk groups, end-of-life care, or the management of hereditary colorectal cancer. Where evidence is available, studies are subject to important differences concerning treatment options, decision criteria, and incongruent assumptions concerning the disease and its management. Conclusions: Across many aspects of the colorectal cancer service, current practice appears to have emerged without the consideration or support of economic evidence. There is a need to develop a common understanding how colorectal cancer models should be structured and implemented.

[1]  P Tappenden,et al.  Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. , 2007, Health technology assessment.

[2]  N Bosanquet,et al.  Short-term costs of conventional vs laparoscopic assisted surgery in patients with colorectal cancer (MRC CLASICC trial) , 2006, British Journal of Cancer.

[3]  W. Scheithauer,et al.  Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial , 2006, British Journal of Cancer.

[4]  J Chilcott,et al.  Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review. , 2010, Health technology assessment.

[5]  C. Carroll,et al.  The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. , 2007, European journal of cancer.

[6]  P. Tappenden,et al.  The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. , 2008, Health technology assessment.

[7]  D. Whynes,et al.  Retesting positive results in screening for colorectal cancer: a marginal analysis , 1991 .

[8]  P. Ewings,et al.  Randomized clinical trial comparing laparoscopic and open surgery for colorectal cancer within an enhanced recovery programme , 2006, The British journal of surgery.

[9]  S. Beard,et al.  Hepatic Resection for Colorectal Liver Metastases: A Cost-Effectiveness Analysis , 2000, Annals of surgery.

[10]  A. Williams,et al.  Assessment of faecal occult blood loss by qualitative and quantitative methods. , 2002, Journal of the Royal College of Surgeons of Edinburgh.

[11]  J. Almond,et al.  The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer , 2007, British Journal of Cancer.

[12]  M. McKee,et al.  Options for Screening for Colorectal Cancer in the Royal Air Force: A Cost-effectiveness Evaluation , 1995, Journal of the Royal Army Medical Corps.

[13]  S. Paisley,et al.  Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer , 2006, British Journal of Cancer.

[14]  J. Scholefield,et al.  Risk‐stratified intensive follow up for treated colorectal cancer – realistic and cost saving? , 2008, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[15]  R. Fitzpatrick,et al.  Issues in methodological research: perspectives from researchers and commissioners. , 2001, Health technology assessment.

[16]  Daniel R. Miller,et al.  Final report , 2000 .

[17]  David K Whynes,et al.  Cost-Effectiveness of Screening for Colorectal Cancer: Evidence from the Nottingham Faecal Occult Blood Trial , 2004, Journal of medical screening.

[18]  R. James,et al.  New face for a familiar friend: the deGramont regimen in the treatment of metastatic colorectal cancer given as an outpatient: a feasibility study , 2002 .

[19]  P. Ewings,et al.  The influence of an Enhanced Recovery Programme on clinical outcomes, costs and quality of life after surgery for colorectal cancer , 2006, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[20]  N. Freemantle,et al.  Cost-effectiveness of oxaliplatin in combination with 5-FU/FA compared with 5-FU/FA alone , 2001 .

[21]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .

[22]  A. Horgan,et al.  Preoperative Intensive, Community-Based vs. Traditional Stoma Education: A Randomized, Controlled Trial , 2005, Diseases of the colon and rectum.

[23]  J. Primrose,et al.  Costs of neoadjuvant chemotherapy and surgery in patients with liver metastases from advanced colorectal cancer , 2001 .

[24]  M. Deverill,et al.  Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. , 2008, Health technology assessment.

[25]  D. Kerr,et al.  An economic comparison of the net clinical benefit and treatment costs of raltitrexed and 5-fluorouracil + leucovorin (Mayo regimen) in advanced colorectal cancer , 1999 .

[26]  David K Whynes,et al.  Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer , 2004, BMJ : British Medical Journal.

[27]  I. Durand-zaleski,et al.  Cost‐effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases , 1998, Cancer.

[28]  D. Whynes,et al.  Rehydration of guaiac-based faecal occult blood tests in mass screening for colorectal cancer. An economic perspective. , 1991, Scandinavian journal of gastroenterology.

[29]  S. Maslekar,et al.  Cost analysis of transanal endoscopic microsurgery for rectal tumours , 2007, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[30]  H. Wasan,et al.  An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). , 2007, European journal of cancer.

[31]  D. Whynes,et al.  Cost savings in mass population screening for colorectal cancer resulting from the early detection and excision of adenomas. , 1992, Health economics.

[32]  D. Whynes,et al.  Is an immunological faecal occult blood test better than Haemoccult? A cost-benefit study. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[33]  P. Tappenden,et al.  Option appraisal of population-based colorectal cancer screening programmes in England , 2006, Gut.

[34]  D. Whynes,et al.  Cost-effective screening strategies for colorectal cancer. , 1992, Journal of public health medicine.

[35]  R. Mihai,et al.  Transanal endoscopic microsurgery--impact on the practice of a colorectal surgeon in a district general hospital. , 2005, Annals of the Royal College of Surgeons of England.

[36]  K. D. Vellacott,et al.  Flexible sigmoidoscopy in general practice , 2002, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[37]  A. Horgan,et al.  A prospective case-matched comparison of clinical and financial outcomes of open versus laparoscopic colorectal resection , 2007, Surgical Endoscopy.

[38]  R. Newcombe,et al.  Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? , 2004, British Journal of Cancer.

[39]  Economic evaluation of laparoscopic surgery for colorectal cancer , 2007, International Journal of Technology Assessment in Health Care.

[40]  D. Nowlan,et al.  Costs and benefits. , 1980, Irish medical journal.

[41]  N. Bansback,et al.  A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. , 2002, Health technology assessment.

[42]  D. Cunningham,et al.  Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer , 2002, British Journal of Cancer.

[43]  R. Stephens,et al.  Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer , 2002, British Journal of Cancer.

[44]  D. Whynes,et al.  Filtering Strategies in Mass Population Screening for Colorectal Cancer , 1992, Medical decision making : an international journal of the Society for Medical Decision Making.

[45]  D. Whynes,et al.  The cost of screening for colorectal cancer. , 1991, Journal of epidemiology and community health.

[46]  N. Freemantle,et al.  Cost-effectiveness of combination chemotherapy (oxaliplatin or irinotecan in combination with 5-FU/FA) compared with 5-FU/FA alone , 2001 .

[47]  T. Hickish,et al.  Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. , 1999, European journal of cancer.

[48]  D. Whynes,et al.  Faecal occult blood screening for colorectal cancer: is it cost-effective? , 1998, Health economics.

[49]  D. Cunningham,et al.  Mature results from three large controlled studies with raltitrexed ('Tomudex'). , 1998, British Journal of Cancer.

[50]  J. Brown,et al.  Cost of quality management and information provision for screening: colorectal cancer screening , 2000, Journal of medical screening.

[51]  D. Cunningham,et al.  Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment , 2007, British Journal of Cancer.